NASDAQ:TCBP TC Biopharm (TCBP) Stock Price, News & Analysis $3.17 +0.27 (+9.31%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$2.81▼$4.1550-Day Range$2.07▼$100.0052-Week Range$2.03▼$192.20Volume766,154 shsAverage Volume137,453 shsMarket Capitalization$2.38 millionP/E RatioN/ADividend YieldN/APrice Target$1,400.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial Media TC Biopharm MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside44,064.0% Upside$1,400.00 Price TargetShort InterestHealthy5.72% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTC Biopharm has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1,400.00, TC Biopharm has a forecasted upside of 44,064.0% from its current price of $3.17.Amount of Analyst CoverageTC Biopharm has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.72% of the outstanding shares of TC Biopharm have been sold short.Short Interest Ratio / Days to CoverTC Biopharm has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TC Biopharm has recently decreased by 88.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTC Biopharm does not currently pay a dividend.Dividend GrowthTC Biopharm does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCBP. Previous Next 3.6 News and Social Media Coverage News SentimentTC Biopharm has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for TC Biopharm this week, compared to 0 articles on an average week.Search InterestOnly 5 people have searched for TCBP on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows7 people have added TC Biopharm to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TC Biopharm insiders have not sold or bought any company stock.Percentage Held by Insiders15.80% of the stock of TC Biopharm is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.87% of the stock of TC Biopharm is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here About TC Biopharm Stock (NASDAQ:TCBP)TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.Read More TCBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCBP Stock News HeadlinesDecember 22, 2023 | finance.yahoo.comTC BioPharm Announces Closing of $3.5 Million Public OfferingDecember 19, 2023 | markets.businessinsider.comTC BioPharm Prices Offering Of 1.75 Mln American Depositary SharesDecember 31, 2023 | MarketBeat Internal (Ad)New Year's Sale: Get MarketBeat All Access Free For 30 DaysAccess our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscriptionDecember 19, 2023 | finance.yahoo.comTC BioPharm Announces Pricing of $3.5 Million Public OfferingDecember 18, 2023 | finance.yahoo.comTC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.DNovember 29, 2023 | benzinga.comTC BioPharm (Holdings) Stock (NASDAQ:TCBP) Dividends: History, Yield and DatesNovember 27, 2023 | markets.businessinsider.comTC BioPharm's IND Application For TCB-008 In Acute Myeloid Leukemia Gets FDA ClearanceNovember 27, 2023 | finance.yahoo.comTC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid LeukemiaDecember 31, 2023 | MarketBeat Internal (Ad)New Year's Sale: Get MarketBeat All Access Free For 30 DaysAccess our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscriptionNovember 14, 2023 | finance.yahoo.comTC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB ResultsSeptember 29, 2023 | seekingalpha.comTC Biopharm files to sell 12.94M American Depositary SharesSeptember 5, 2023 | finance.yahoo.comTC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL)August 29, 2023 | finance.yahoo.comTC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment ConferenceMay 4, 2023 | finance.yahoo.comTC Biopharm (Holdings) Full Year 2022 Earnings: Beats ExpectationsApril 30, 2023 | benzinga.comPremarket Mover: TC BioPharm Ltd (TCBP) Down 5.17%April 26, 2023 | finance.yahoo.comTC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008April 20, 2023 | ca.finance.yahoo.comTC Biopharm (Holdings) Plc (TCBP)April 19, 2023 | finance.yahoo.comTC BioPharm to Present at the Sequire Investor Summit in Puerto RicoMarch 16, 2023 | finance.yahoo.comTC BioPharm Receives Extension from Nasdaq Hearings Panel to Regain Compliance With Listing Rule 5550(b)(2)February 16, 2023 | seekingalpha.comTCBP TC Biopharm (Holdings) PlcFebruary 13, 2023 | finance.yahoo.comTC BioPharm to Reschedule Shareholder Update Call and WebcastJanuary 18, 2023 | benzinga.comWhat's Going On With TC BioPharm Stock?January 17, 2023 | finance.yahoo.comTC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in OncologyJanuary 15, 2023 | benzinga.comTC BioPharm Shares Halted On Circuit Breaker To The Upside, Stock Now Up 78.9%December 20, 2022 | finance.yahoo.comTC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder UpdateNovember 28, 2022 | finance.yahoo.comTC BioPharm Announces $7.35 Million Private PlacementNovember 21, 2022 | finance.yahoo.comTC Biopharm (Holdings) Plc's (NASDAQ:TCBP) biggest owners are individual investors who got richer after stock soared 11% last weekSee More Headlines Receive TCBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCBP CUSIPN/A CIK1872812 Webwww.tcbiopharm.com Phone44-14-1433-7557FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$1,400.00 High Stock Price Target$1,400.00 Low Stock Price Target$1,400.00 Potential Upside/Downside+44,064.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.83 Current Ratio1.09 Quick RatioN/A Sales & Book Value Annual Sales$4.76 million Price / Sales0.50 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book-4.73Miscellaneous Outstanding Shares750,000Free Float633,000Market Cap$2.38 million OptionableNot Optionable Beta0.32 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Bryan L. Kobel (Age 42)CEO & Director Mr. Martin E. Thorp (Age 71)CFO & Director Mr. Christopher CamarraExecutive Vice President of CommunicationsKey CompetitorsIgnyte AcquisitionNASDAQ:IGNYCalithera BiosciencesNASDAQ:CALAHumanigenNASDAQ:HGENBruush Oral CareNASDAQ:BRSHSenesTechNASDAQ:SNESView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 230,813 shares on 11/15/2023Ownership: 31.316%View All Institutional Transactions TCBP Stock Analysis - Frequently Asked Questions Should I buy or sell TC Biopharm stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TC Biopharm in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCBP shares. View TCBP analyst ratings or view top-rated stocks. What is TC Biopharm's stock price target for 2024? 1 brokers have issued 1-year price objectives for TC Biopharm's stock. Their TCBP share price targets range from $1,400.00 to $1,400.00. On average, they predict the company's share price to reach $1,400.00 in the next twelve months. This suggests a possible upside of 44,064.0% from the stock's current price. View analysts price targets for TCBP or view top-rated stocks among Wall Street analysts. How have TCBP shares performed in 2023? TC Biopharm's stock was trading at $770.00 on January 1st, 2023. Since then, TCBP stock has decreased by 99.6% and is now trading at $3.17. View the best growth stocks for 2023 here. When did TC Biopharm's stock split? TC Biopharm's stock reverse split on Friday, December 15th 2023. The 1-20 reverse split was announced on Friday, December 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did TC Biopharm IPO? (TCBP) raised $17 million in an initial public offering on Friday, February 11th 2022. The company issued 4,100,000 shares at a price of $4.25 per share. EF Hutton served as the underwriter for the IPO. How do I buy shares of TC Biopharm? Shares of TCBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCBP) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TC Biopharm (Holdings) Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.